<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499822</url>
  </required_header>
  <id_info>
    <org_study_id>09F401</org_study_id>
    <nct_id>NCT02499822</nct_id>
  </id_info>
  <brief_title>REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial</brief_title>
  <acronym>REVERENT</acronym>
  <official_title>Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Auxologico Italiano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Auxologico Italiano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is

        1. to compare the effects of nifedipine GITS and ramipril on blood pressure variability in
           subjects with elevated blood pressure variability.

        2. to assess whether the degree of treatment-induced changes in blood pressure variability,
           is related to the degree of regression (or progression) of organ damage in heart,
           kidneys and carotid arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevated blood pressure variability (BPV) is associated with adverse cardiovascular outcomes
      and organ damage in hypertensive subjects. An antihypertensive treatment able to reduce BPV
      independently of BP lowering effect might thus provide additional protection in terms of
      cardiovascular risk in subjects with elevated BPV, independently on its effect of BP itself.
      However, data on the effects of different classes of antihypertensive drugs on BPV are
      limited and inconsistent. Some studies have suggested a possible usefulness of calcium
      antagonists in this setting. Based on the above considerations the investigators hypothesize
      that a calcium channel blocker nifedipine GITS, will provide a greater BPV lowering effect,
      when compared with ramipril, independently from the reduction in mean BP level. Based on the
      above considerations, the primary objective of this study is to compare the effects of
      nifedipine GITS and ramipril on different estimates of BPV (24 h BPV, home BPV, and
      visit-to-visit BPV) in subjects with elevated BPV. The secondary objective is to assess
      whether the degree of treatment-induced changes in BPV, is related to the degree of
      regression (or progression) of organ damage, after accounting for mean BP reduction by
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variability (standard deviation) of home systolic blood pressure at final visit</measure>
    <time_frame>After 10 weeks of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variability (standard deviation) of home diastolic blood pressure measured at final visit</measure>
    <time_frame>At baseline and after 10 weeks of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short term 24h variability of systolic blood pressure at final visit (24h weighted standard deviation)</measure>
    <time_frame>At baseline and after 10 weeks of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short term 24h variability of diastolic blood pressure at final visit (24h weighted standard deviation)</measure>
    <time_frame>At baseline and after 10 weeks of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visit-to-visit variability (standard deviation) of systolic blood pressure assessed over the three last visits</measure>
    <time_frame>At baseline and after 6, 8 and 10 weeks of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visit-to-visit variability (standard deviation) of diastolic blood pressure assessed over the three last visits</measure>
    <time_frame>At baseline and after 6, 8 and 10 weeks of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24 hour systolic blood pressure at final visit</measure>
    <time_frame>At baseline and after 10 weeks of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24 hour diastolic blood pressure at final visit</measure>
    <time_frame>At baseline and after 10 weeks of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sokolow index at the end of the extension study</measure>
    <time_frame>At baseline and after 12 months of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cornell voltage duration index at the end of the extension study</measure>
    <time_frame>At baseline and after 12 months of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass index at the end of the extension study</measure>
    <time_frame>At baseline and after 12 months of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microalbuminuria (albumin-creatinine ratio) at the end of the extension study</measure>
    <time_frame>At baseline and after 12 months of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR, by CKD-EPI formula) at the end of the extension study</measure>
    <time_frame>At baseline and after 12 months of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid-femoral pulse wave velocity (cfPWV) at the end of the extension study</measure>
    <time_frame>At baseline and after 12 months of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Hypertension</condition>
  <condition>High Blood Pressure Variability</condition>
  <arm_group>
    <arm_group_label>Nifedipine GITS 30 mg slow release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifedipine GITS 30 mg slow release in tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramipril 10 mg in tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine GITS</intervention_name>
    <description>Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.</description>
    <arm_group_label>Nifedipine GITS 30 mg slow release</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.</description>
    <arm_group_label>Ramipril 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects

          -  Age 35-75 years

          -  Clinic systolic BP ≥140 mmHg and/or diastolic BP ≥ 90 mmHg (under no antihypertensive
             treatment)

          -  Daytime BP on ambulatory BP monitoring (ABPM) ≥135 mmHg systolic and/or ≥85 mmHg
             diastolic (under no antihypertensive treatment)

          -  Home SBP standard deviation (SD) &gt;7 mmHg and/or daytime ambulatory SBP SD &gt;12 mmHg

          -  Patients may be included if untreated or, if treated with one antihypertensive drug or
             two drugs in low doses, after 2 weeks' washout period

          -  Written informed consent to participate in the study

        Exclusion Criteria:

          -  Subjects treated with ≥ 2 antihypertensive drugs (except those on two drugs in low
             doses)

          -  Treated subjects with on-treatment clinic BP ≥160 mmHg systolic and/or 100 mmHg
             diastolic

          -  Treated antihypertensive subjects in whom withdrawal of treatment is deemed unethical
             by the investigator (e.g. because of the existence of compelling indications other
             than hypertension for continuous use of previously used antihypertensive agent)

          -  Contraindications to study treatments as detailed in the relative Summaries of Medical
             Product Characteristics for ramipril (hypersensitivity to ramipril or any of the
             excipients or any other ACE inhibitor, history of angioneurotic oedema, extracorporeal
             treatments leading to contact of blood with negatively charged surfaces, significant
             bilateral renal artery stenosis or renal artery stenosis in a single functioning
             kidney, second and third trimesters of pregnancy, lactation, haemodynamically relevant
             renal artery stenosis, hypotensive or haemodynamically unstable patients) or
             nifedipine GITS (known hypersensitivity to nifedipine or to any of the excipients,
             pregnancy before week 20 and during breastfeeding, cardiovascular shock, concomitant
             treatment with rifampicin, patients with a Kock pouch)

          -  Cardiovascular diseases other than hypertension (coronary heart disease, heart failure
             or left ventricular systolic dysfunction of any degree, atrial fibrillation or
             frequent arrhythmias, valvular or congenital heart disease, cardiomyopathies,
             cerebrovascular disease, peripheral artery disease, aortic aneurysm)

          -  Chronic kidney disease

          -  Suspected or confirmed secondary hypertension

          -  Diabetes mellitus

          -  Subjects with conditions other than those mentioned above, where compelling
             indications for the use of any specific class of antihypertensive medication exist,
             according to current (e.g. European Society of Cardiology) guidelines

          -  Other conditions deemed relevant by the investigator (including respiratory disorders,
             liver disease, renal disease, thyroid disorders)

          -  BMI ≥35 kg/m2

          -  Known severe obstructive sleep apnea (apnea-hypopnea index &gt; 30 or use of CPAP)

          -  Premenopausal women not using effective contraceptive methods

          -  Elevated probability of noncompliance with the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianfranco Parati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Auxologico Italiano - Milan, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianfranco Parati, MD</last_name>
    <phone>390261911</phone>
    <phone_ext>2890</phone_ext>
    <email>gianfranco.parati@unimib.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Grzegorz Bilo, MD</last_name>
    <phone>390261911</phone>
    <phone_ext>2903</phone_ext>
    <email>g.bilo@auxologico.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital Shanghai Institute of Hypertension, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiguang Wang, MD</last_name>
      <email>jiguangwang@aim.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hypertension Center, Third University Department of Medicine, Sotiria Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George S Stergiou, MD</last_name>
      <email>gstergi@med.uoa.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Auxologico Italiano</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianfranco Parati, MD</last_name>
      <phone>390261911</phone>
      <phone_ext>2890</phone_ext>
      <email>gianfranco.parati@unimib.it</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Greece</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.</citation>
    <PMID>23817082</PMID>
  </reference>
  <reference>
    <citation>Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013 Mar;10(3):143-55. doi: 10.1038/nrcardio.2013.1. Epub 2013 Feb 12. Review. Erratum in: Nat Rev Cardiol. 2014 Jun;11(6):314.</citation>
    <PMID>23399972</PMID>
  </reference>
  <reference>
    <citation>Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens. 2003 Oct;21(10):1961-7.</citation>
    <PMID>14508204</PMID>
  </reference>
  <reference>
    <citation>Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010 Mar 13;375(9718):895-905. doi: 10.1016/S0140-6736(10)60308-X.</citation>
    <PMID>20226988</PMID>
  </reference>
  <reference>
    <citation>Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010 Mar 13;375(9718):906-15. doi: 10.1016/S0140-6736(10)60235-8. Review.</citation>
    <PMID>20226989</PMID>
  </reference>
  <reference>
    <citation>Ushigome E, Fukui M, Hamaguchi M, Tanaka T, Atsuta H, Ohnishi M, Oda Y, Yamazaki M, Hasegawa G, Nakamura N. Beneficial effect of calcium channel blockers on home blood pressure variability in the morning in patients with type 2 diabetes. J Diabetes Investig. 2013 Jul 8;4(4):399-404. doi: 10.1111/jdi.12052. Epub 2013 Mar 4.</citation>
    <PMID>24843686</PMID>
  </reference>
  <reference>
    <citation>Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens. 2014 May;8(5):340-9. doi: 10.1016/j.jash.2014.02.004. Epub 2014 Feb 15. Review.</citation>
    <PMID>24685006</PMID>
  </reference>
  <reference>
    <citation>Levi-Marpillat N, Macquin-Mavier I, Tropeano AI, Parati G, Maison P. Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension. Hypertens Res. 2014 Jun;37(6):585-90. doi: 10.1038/hr.2014.33. Epub 2014 Mar 27.</citation>
    <PMID>24671016</PMID>
  </reference>
  <reference>
    <citation>Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012 Jun;30(6):1241-51. doi: 10.1097/HJH.0b013e32835339ac.</citation>
    <PMID>22499291</PMID>
  </reference>
  <reference>
    <citation>Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension. 2012 Jun;59(6):1132-8. doi: 10.1161/HYPERTENSIONAHA.111.189217. Epub 2012 Apr 30.</citation>
    <PMID>22547439</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Blood pressure variability</keyword>
  <keyword>Home systolic blood pressure</keyword>
  <keyword>Organ damage</keyword>
  <keyword>Nifedipine GITS</keyword>
  <keyword>Ramipril</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

